Who are Eplivanserin (SR46349)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): quetiapine fumarate vs risperidone, Intramuscular aripiprazole, olanzapine, quetiapine (Seroquel) XR, full-dose olanzapine, Quetiapine Immediate Release, Risperidone, Haloperidol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eplivanserin-sr46349.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Eplivanserin (SR46349) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eplivanserin (SR46349) (Eplivanserin (SR46349)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT2A receptor antagonist. Area: Sexual Health / Urology.

phase 3 5-HT2A receptor antagonist 5-HT2A receptor Sexual Health / Urology Small molecule Live · refreshed every 30 min

Target snapshot

Eplivanserin (SR46349) (Eplivanserin (SR46349)) — Sanofi. Eplivanserin is a selective serotonin 5-HT2A receptor antagonist that modulates serotonergic signaling to treat sexual dysfunction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Eplivanserin (SR46349) TARGET	Eplivanserin (SR46349)	Sanofi	phase 3	5-HT2A receptor antagonist	5-HT2A receptor
quetiapine fumarate vs risperidone	quetiapine fumarate vs risperidone	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Intramuscular aripiprazole, olanzapine	Intramuscular aripiprazole, olanzapine	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
quetiapine (Seroquel) XR	quetiapine (Seroquel) XR	Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
full-dose olanzapine	full-dose olanzapine	Kaohsiung Kai-Suan Psychiatric Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine Immediate Release	Quetiapine Immediate Release	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone, Haloperidol	Risperidone, Haloperidol	Ludwig-Maximilians - University of Munich	marketed	Antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT2A receptor antagonist class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eplivanserin (SR46349) — Competitive Intelligence Brief. https://druglandscape.com/ci/eplivanserin-sr46349. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing